Endra Life Sciences Inc (NDRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,230 | 4,745 | 6,401 | 1,135 | 2,834 |
| TOTAL | $3,434 | $4,962 | $6,714 | $1,271 | $3,033 |
| Non-Current Assets | |||||
| PPE Net | 69 | 80 | 92 | 112 | 112 |
| Other Non-Current Assets | 949 | 3,337 | 3,637 | 3,679 | 3,610 |
| TOTAL | $1,019 | $3,417 | $3,729 | $3,790 | $3,721 |
| Total Assets | $4,452 | $8,379 | $10,443 | $5,061 | $6,754 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 29 |
| Accounts payable and accrued liabilities | 508 | 627 | 1,167 | 1,039 | 701 |
| TOTAL | $605 | $814 | $1,350 | $1,217 | $903 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,287 | 960 | 98 | 146 | 192 |
| TOTAL | $1,287 | $960 | $98 | $146 | $192 |
| Total Liabilities | $1,892 | $1,774 | $1,449 | $1,363 | $1,095 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 562 | 537 | 41 | 6 | 6 |
| Common Shares | 0 | 0 | 7 | 1 | 0 |
| Retained earnings | -103,438 | -99,289 | -96,935 | -94,706 | -91,930 |
| Other shareholders' equity | 0 | 0 | 0 | 0 | 5 |
| TOTAL | $2,560 | $6,605 | $8,994 | $3,698 | $5,659 |
| Total Liabilities And Equity | $4,452 | $8,379 | $10,443 | $5,061 | $6,754 |